Skip to main navigation Skip to search Skip to main content

Exploring the Binding Pathway of Novel Nonpeptidomimetic Plasmepsin V Inhibitors

  • Raitis Bobrovs*
  • , Laura Drunka
  • , Iveta Kanepe
  • , Aigars Jirgensons
  • , Amedeo Caflisch
  • , Matteo Salvalaglio
  • , Kristaps Jaudzems
  • *Corresponding author for this work
  • Latvian Institute of Organic Synthesis
  • University of Zurich
  • University College London

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Predicting the interaction modes and binding affinities of virtual compound libraries is of great interest in drug development. It reduces the cost and time of lead compound identification and selection. Here we apply path-based metadynamics simulations to characterize the binding of potential inhibitors to the Plasmodium falciparum aspartic protease plasmepsin V (plm V), a validated antimalarial drug target that has a highly mobile binding site. The potential plm V binders were identified in a high-throughput virtual screening (HTVS) campaign and were experimentally verified in a fluorescence resonance energy transfer (FRET) assay. Our simulations allowed us to estimate compound binding energies and revealed relevant states along binding/unbinding pathways in atomistic resolution. We believe that the method described allows the prioritization of compounds for synthesis and enables rational structure-based drug design for targets that undergo considerable conformational changes upon inhibitor binding.

Original languageEnglish
Pages (from-to)6890-6899
Number of pages10
JournalJournal of Chemical Information and Modeling
Volume63
Issue number21
DOIs
Publication statusPublished - 13 Nov 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Exploring the Binding Pathway of Novel Nonpeptidomimetic Plasmepsin V Inhibitors'. Together they form a unique fingerprint.

Cite this